BRIEF — Levosert license extended in UK

The UK license for prescribing Levosert (levonorgestrel intrauterine system) has been extended to five years in its indications for contraception and the treatment of heavy menstrual bleeding.

Hungary's largest drugmaker Gedeon Richter (RICHT: HB) has welcomed this option to allow women freedom to not worry about the risk of unplanned pregnancies for up to five years.

The license extension was based on new data that studied the efficacy and safety of Levosert in 1,751 women aged 16 to 45 years old, and showed that it is effective and well-tolerated over five years of use.